Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

Abstract

PD-1/PD-L1 inhibitor plus nab-paclitaxel resulted in significantly longer OS and higher response <i>versus</i> ICI single agent in metastatic NSCLC patients who have progressed after platinum-based chemotherapy. These findings need to be further explored by prospective studies.